CombiGene’s CEO Jan Nilsson describes how the collaboration and licensing agreement with Spark Therapeutics creates new business development opportunities at Stora Aktiedagen Stockholm November 30, at 16.30

News 2021 2021   2020   2019   2018   2017   2016   2015   The agreement provides Spark with the exclusive world-wide license to develop, manufacture and commercialize CG01. Under the terms of agreement, CombiGene is eligible to receive up to $328.5 million...

read more

CombiGene AB (publ): Nominating committee

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015   The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2021 The AGM 2021 resolved that a nominating committee should be...

read more

Interim Report January – September 2021

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013   Interim Report January – September 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a...

read more

CombiGene’s Karin Agerman talks about ATMP in new NLS article

News 2021 2021   2020   2019   2018   2017   2016   2015   In a new NLS article, Karin Agerman, Chief Research & Development Officer at CombiGene, and Tony Hitchcock, Technical Director at Cobra Biologics, a Charles River Company, explores the effects of the...

read more

Ingeneious #3 2021, News from CombiGene

Genevägen 2021 2021   2020   2019   2018   2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel...

read more

October 7, Vator Securities Healthcare Innovation Summit

2021   2020   2019   2018   2017   2016   2015 Jan Nilsson will present CombiGene on Vator Securities Healthcare Innovation Summit vatorsecurities.se/event/vator-securities-healthcare-innovation-summit/ Om CombiGene CombiGenes vision är att erbjuda patienter som...

read more

Interim Report January – June 2021

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Interim Report January – June 2021>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...

read more

Biostock: CombiGene’s CEO on this summer’s news

2021   2020   2019   2018   2017   2016   2015 "The gene therapy company CombiGene ended July with two significant pieces of news. Firstly, the company has started GMP production of the drug candidate CG01 for the first clinical study that begin next year. Secondly,...

read more

GMP plasmids released – Ready to start GMP production of CG01

2021   2020   2019   2018   2017   2016   2015 Cobra Biologics (Cobra), the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic...

read more

Record date for reverse share split in CombiGene

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 The Board of Directors of CombiGene AB (publ) ("CombiGene") has resolved that the record date for the reverse share split shall be 8 June. Through the reverse share split, twenty (20) existing shares...

read more

The EU continues to invest in CombiGene

2021   2020   2019   2018   2017   2016   2015   This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> CombiGene’s epilepsy project CG01 has already been granted EUR 3.36 million by the EU programme Horizon 2020. Now the EU is...

read more

Gunilla Lundmark new board member of CombiGene

News 2021 2021   2020   2019   2018   2017   2016   2015 At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions...

read more

First in human study within reach

News 2021 2021   2020   2019   2018   2017   2016   2015   This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> A lot has happened at CombiGene during the first months of 2021 and when Ingeneious gets the opportunity to talk to...

read more

Bulletin from the annual general meeting of CombiGene AB (publ)

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ) (“CombiGene”) on 25 May 2021. Adoption of income statement and balance sheet and discharge from...

read more

Ingeneious #2 2021, News from CombiGene

Ingeneious 2021 2021   2020   2019   2018   2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement...

read more

Interim Report January – March 2021

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Interim Report January – March 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...

read more

CombiGene annual report 2020

Financial reports 2021 2021   2020   2019   2018   2017   2016   2015   2014   2013 Annual report 2020>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene...

read more

Notice of annual general meeting in CombiGene

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of CombiGene AB (publ) are hereby summoned to...

read more

CombiGene announces outcome in rights issue

Regulatory news 2021 2021   2020   2019   2018   2017   2016   2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...

read more

Today, CombiGene Celebrates the World Lipodystrophy Day

News 2021 2021   2020   2019   2018   2017   2016   2015 Currently, there is no cure for lipodystrophy, and just the secondary complications can be treated. Lipodystrophy is a rare and very serious disease. CombiGene continues to develop the pre-clinical work in the...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook